Mode
Text Size
Log in / Sign up
Phase 3 N=116 Randomized Quadruple-blind Treatment

Does Montelukast Decrease Post Adenotonsillectomy Pain in Children

Pain

Enrolled (actual)
116
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Postoperative Physician Contacts — 20; 24 participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Montelukast (Drug); Placebo (Drug)
Age
Pediatric · 3+ yrs
Sex
All
Sponsor
Children's Hospital Medical Center, Cincinnati
Primary completion
Nov 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Postoperative Physician Contacts
20; 24
SECONDARY
Pain Scores
1.9; 1.8

Summary

Objective: The purpose of the present study is to evaluate the effectiveness of preoperative Montelukast as an analgesic for adenotonsillectomy Study Design: Randomized controlled double blinded clinical trial. Setting: Cincinnati Children's Hospital Medical Center (CCHMC), Division of Pediatric Otolaryngology, Head and Neck Surgery Methods: Children between the age of 3-8 undergoing adenotonsillectomy with planned 23 hour observation for adenotonsillar hypertrophy and sleep disordered breathing will be randomized to receive either montelukast or placebo in Same Day surgery. Analysis: Differences in demographics (age, gender, race, weight) between the intervention and control groups will be assessed using chi-square (for categorical measures) and t tests (for continuous measures). Differences in postoperative opioid usage, postoperative pain scores using the FLACC scale, and the number of postoperative contacts (Emergency department visits or phone calls) with patients or their family regarding pain or tonsillar hemorrhage will be evaluated using chi-square (categorical measures) and t tests (continuous measures).

Eligibility Criteria

Inclusion Criteria: All patients between the ages of 3-8 undergoing adenotonsillectomy for an indication of adenotonsillar hypertrophy who are scheduled for overnight 23 hour observation at CCHMC main campus. Exclusion Criteria: Patients with moderate to severe developmental delay will be excluded due to difficulties in scoring postoperative pain. In addition, those with allergies to Montelukast and those currently using Montelukast will be excluded. Those with moderate to severe cardiac, hepatic, pulmonary or renal disease will be excluded. All patients with a primary indication of chronic tonsillitis will be excluded. Those with active respiratory infections requiring cancellation of surgery will be excluded based on the Anesthesia services recommendations.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02793375). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search